Global Blood Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, GBT, Global Blood Therapeutics Inc, priceseries

Global Blood Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
27.40
Close
27.88
High
28.61
Low
27.40
Previous Close
27.53
Daily Price Gain
0.35
YTD High
34.82
YTD High Date
Feb 16, 2022
YTD Low
25.21
YTD Low Date
Jan 24, 2022
YTD Price Change
-2.58
YTD Gain
-8.47%
52 Week High
46.96
52 Week High Date
Mar 16, 2021
52 Week Low
24.61
52 Week Low Date
Dec 14, 2021
52 Week Price Change
-11.06
52 Week Gain
-28.40%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 7. 2017
16.80
Mar 29. 2017
37.90
35 Trading Days
125.58%
Link
LONG
Sep 27. 2017
28.50
Oct 19. 2017
31.69
16 Trading Days
11.19%
Link
LONG
Oct 24. 2017
33.20
Nov 10. 2017
38.71
13 Trading Days
16.59%
Link
LONG
Jan 9. 2018
47.15
Jan 31. 2018
58.14
15 Trading Days
23.32%
Link
LONG
Aug 14. 2018
46.40
Aug 29. 2018
49.21
11 Trading Days
6.06%
Link
LONG
Mar 28. 2019
52.00
Apr 15. 2019
57.56
12 Trading Days
10.69%
Link
LONG
Sep 4. 2019
47.49
Sep 26. 2019
52.75
16 Trading Days
11.07%
Link
LONG
Nov 12. 2019
48.38
Dec 18. 2019
73.95
25 Trading Days
52.85%
Link
LONG
Apr 3. 2020
52.66
May 1. 2020
72.86
19 Trading Days
38.36%
Link
LONG
Sep 30. 2020
55.14
Oct 12. 2020
59.75
8 Trading Days
8.37%
Link
LONG
Oct 7. 2021
27.81
Oct 20. 2021
30.02
9 Trading Days
7.96%
Link
LONG
Oct 27. 2021
32.78
Nov 5. 2021
35.80
7 Trading Days
9.20%
Link
LONG
Feb 7. 2022
28.80
Feb 22. 2022
31.53
10 Trading Days
9.47%
Link
Company Information
Stock Symbol
GBT
Exchange
NasdaqGS
Company URL
http://www.globalbloodtx.com
Company Phone
650741-7700
CEO
Ted W. Love
Headquarters
California
Business Address
400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO, CA 94080
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001629137
About

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

Description

Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease (SCD) in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. The company is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities. Global Blood Therapeutics Inc. was founded in 2011 and is headquartered in South San Francisco, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading